A Study to Evaluate ALN-4915 in Adult Healthy Volunteers
← catalyst calendarNCT07535606 · readout in 346 d
Sponsored by Alnylam Pharmaceuticals (industry) · ALNY — their whole pipeline →.
Phase
Phase 1
Status
Recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
44estimated
Sites
1
Country
United Kingdom
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-02 | actual | When the study began enrolling |
| Primary completion | 2027-07-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-07-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Healthy Volunteers
Interventions
- Drug: ALN-4915
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFFrequency of Adverse Events
measured Serious adverse events (SAEs) after signing of ICF up to Month 12; nonserious AEs after first dose of study drug up to Month 12
Permalink · ALNY's whole pipeline · Catalyst calendar · Every registered study · What changed